TY - JOUR
T1 - Ferulic acid enhances nitric oxide production through up-regulation of argininosuccinate synthase in inflammatory human endothelial cells
AU - Zhao, Jian
AU - Suyama, Aki
AU - Chung, Hsuan
AU - Fukuda, Toshihiko
AU - Tanaka, Mitsuru
AU - Matsui, Toshiro
N1 - Funding Information:
This study was supported by a Grant-in-aid for young scientists (B) (No. 24780130 ) to MT. The authors thank Dr. Masao Sato and Ms. Kaori Miyazaki for their technical assistance. The cost of publication was supported in part by the Research Grant for Young Investigators of Faculty of Agriculture, Kyushu University.
PY - 2016/1/15
Y1 - 2016/1/15
N2 - Aim In this study, we investigated the protective effect of ferulic acid (FA) on nitric oxide (NO) production in tumor necrosis factor (TNF)-α-stimulated inflammatory human umbilical vein endothelial cells (HUVECs), and elucidated the mechanism(s) involved. Main methods The TNF-α-stimulated inflammatory HUVECs were treated with acetylcholine (ACh) and/or FA. NO productions were measured by monitoring nitrite and nitrate using a 2,3-diaminonaphthalene Kit. Expressions of mRNA and proteins were evaluated by RT-PCR and Western blotting, respectively. Key findings FA treatment resulted in a dose-dependent (10-200 μM) restoration of ACh-mediated NO production in TNF-α-treated HUVECs, whereas treatment with the FA analogues, coumaric acid, and apocynin resulted in no significant effect. FA treatment had no effect on O2- production in TNF-α-stimulated HUVECs. NG-monomethyl-l-arginine acetate (a nitric oxide synthase (NOS) inhibitor) and α-methyl-dl-aspartic acid (an argininosuccinate synthase (ASS) inhibitor) counteracted the effects of FA on the NO production. While FA treatment did not significantly affect the protein expression of p-eNOS or eNOS, the protein expression of ASS as well as mRNA expression was restored to normal levels upon exposure to FA in TNF-α-stimulated HUVECs. In nucleus, FA attenuated the increase of nuclear factor-kappa B (NF-κB) expression by TNF-α. Significance FA treatment rescues the defect in ACh-induced NO production resulting from TNF-α-stimulation in inflammatory HUVECs. This effect was likely due, in part, to the FA-mediated up-regulation of ASS expression via the suppression of NF-κB inflammatory signaling cascade.
AB - Aim In this study, we investigated the protective effect of ferulic acid (FA) on nitric oxide (NO) production in tumor necrosis factor (TNF)-α-stimulated inflammatory human umbilical vein endothelial cells (HUVECs), and elucidated the mechanism(s) involved. Main methods The TNF-α-stimulated inflammatory HUVECs were treated with acetylcholine (ACh) and/or FA. NO productions were measured by monitoring nitrite and nitrate using a 2,3-diaminonaphthalene Kit. Expressions of mRNA and proteins were evaluated by RT-PCR and Western blotting, respectively. Key findings FA treatment resulted in a dose-dependent (10-200 μM) restoration of ACh-mediated NO production in TNF-α-treated HUVECs, whereas treatment with the FA analogues, coumaric acid, and apocynin resulted in no significant effect. FA treatment had no effect on O2- production in TNF-α-stimulated HUVECs. NG-monomethyl-l-arginine acetate (a nitric oxide synthase (NOS) inhibitor) and α-methyl-dl-aspartic acid (an argininosuccinate synthase (ASS) inhibitor) counteracted the effects of FA on the NO production. While FA treatment did not significantly affect the protein expression of p-eNOS or eNOS, the protein expression of ASS as well as mRNA expression was restored to normal levels upon exposure to FA in TNF-α-stimulated HUVECs. In nucleus, FA attenuated the increase of nuclear factor-kappa B (NF-κB) expression by TNF-α. Significance FA treatment rescues the defect in ACh-induced NO production resulting from TNF-α-stimulation in inflammatory HUVECs. This effect was likely due, in part, to the FA-mediated up-regulation of ASS expression via the suppression of NF-κB inflammatory signaling cascade.
UR - http://www.scopus.com/inward/record.url?scp=84954570745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954570745&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2015.12.044
DO - 10.1016/j.lfs.2015.12.044
M3 - Article
C2 - 26731042
AN - SCOPUS:84954570745
SN - 0024-3205
VL - 145
SP - 224
EP - 232
JO - Life Sciences
JF - Life Sciences
ER -